| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b54b92c92292765bcf5a0861a7f5539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b4609f484a1460dfba40f533029c5d1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2017-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d08b41bf43c919c7f596df29e5873a88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_622034ebeab4c1cf574ad2bf60547186 |
| publicationDate |
2019-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10478442-B2 |
| titleOfInvention |
Method for the treatment of Dravet Syndrome |
| abstract |
A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11571397-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11634377-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11458111-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11786487-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021156437-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11759440-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11673852-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11406606-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11612574-B2 |
| priorityDate |
2013-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |